Last Updated : October 17, 2024
Listed are current opportunities for patient groups, clinician groups, drug plans, and cancer agencies to provide input or feedback on drugs being assessed within the reimbursement review process.
Input is information, insight, or advice given to us to contribute to a review. Feedback is a response to a prepared proposal, review report, or draft recommendation.
Therapeutic Area: Acne vulgaris
Draft recommendations posted for stakeholder feedback: October 17, 2024
End of feedback period: October 31, 2024
Draft Recommendation
Therapeutic Area: Genito-urinary cancer (prostate cancer)
Draft recommendations posted for stakeholder feedback: October 17, 2024
End of feedback period: October 31, 2024
Draft Recommendation
Therapeutic Area: Tuberous Sclerosis Complex (TSC)
Draft recommendations posted for stakeholder feedback: October 17, 2024
End of feedback period: October 31, 2024
Draft Recommendation